Faeth Therapeutics, Inc. Research and Development Expense
Faeth Therapeutics, Inc. (FTH) reported Research and Development Expense of $3.37 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-05-13
- Faeth Therapeutics, Inc. research and development expense for the quarter ending 2021-03-31 was $3.37M, a 53.30% increase year-over-year.
- Faeth Therapeutics, Inc. research and development expense for the quarter ending 2020-03-31 was $2.19M.
| Period end | Research and Development Expense 3 month |
|---|---|
| 2021-03-31 | $3.37M 10-Q · filed 2021-05-13 |
| 2020-03-31 | $2.19M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |